A Phase 1/2, Open-Label Clinical Study To Evaluate Safety And Efficacy Of TP-0184 To Treat Anemia When Administered To Adult Patients With IPSS-R Low Or Intermediate Risk Myelodysplastic Syndromes
Latest Information Update: 18 Oct 2023
At a glance
- Drugs Itacnosertib (Primary)
- Indications Anaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sumitomo Pharma Oncology
- 06 Mar 2023 Status changed from completed to discontinued.
- 04 Apr 2022 Status changed from active, no longer recruiting to completed.
- 06 Jan 2022 Planned End Date changed from 1 Sep 2023 to 30 Dec 2021.